RA
CORZ icon

REX Advisers’s Core Scientific CORZ Stock Holding History

REX Advisers’s Portfolio CORZ Stock Details CORZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-66,200
Closed -$1.69M – 48
2026
Q2 		$1.69M Buy
+66,200
New +$1.56M 3.83% 19
2026
Q1 		– Sell
-27,200
Closed -$396K – 83
2025
Q4 		$396K Buy
+27,200
New +$474K 1.67% 19

Other funds holding CORZ

TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
MNBTD
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 28.25% 1-Year Est. Return
SCP
Silverleafe Capital Partners Germantown, Tennessee $351M AUM 24.63% 1-Year Est. Return
GA
GoalVest Advisory New York $578M AUM 17.41% 1-Year Est. Return
TAM
Titleist Asset Management San Antonio, Texas $1.55B AUM 13.34% 1-Year Est. Return
BAM
Byrne Asset Management Kingston, New Jersey $179M AUM 29.67% 1-Year Est. Return
TA
Tactive Advisors Jacksonville, Florida $416M AUM 26.3% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

REX Advisers's CORZ Position: Q3 2026 in Review

REX Advisers sold out of Core Scientific (CORZ) in Q3 2026, closing a stake of 66,200 shares — an estimated $1.69M sold.

REX Advisers first reported a position in CORZ in Q4 2025 and held it in 2 quarters. The position peaked at $1.69M in Q2 2026. 13 funds tracked by Wall St. Rank hold CORZ as of Q3 2026.

  • REX Advisers reported no remaining Core Scientific position as of Q3 2026 after selling out during the quarter.
  • REX Advisers sold 66,200 Core Scientific shares in Q3 2026, an estimated $1.69M.
  • REX Advisers first reported a position in Core Scientific in Q4 2025 and held it in 2 quarters.
  • REX Advisers's Core Scientific position peaked at $1.69M in Q2 2026.
  • 13 funds tracked by Wall St. Rank held Core Scientific as of Q3 2026.

Based on REX Advisers's 13F filing for Q3 2026, filed 8 Oct 2026.